Neuronetics is expected to report Q2 2026 revenue of $21.40 million and a loss per share of $0.11, with the current stock price of $1.25 trailing significantly behind the $4.50 analyst consensus price target.
The central focus for investors remains the growth of recurring treatment session revenue, which serves as a primary indicator of system utilization and long-term profitability.
Following the recent FDA clearance for adolescent use, analysts are looking for evidence that this new patient demographic is accelerating system adoption. Furthermore, the company's progress toward achieving positive cash flow remains a vital narrative as it manages its capital structure.